Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Braden Michael Leonard Acquires 107,434 Shares

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard acquired 107,434 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were purchased at an average cost of $1.14 per share, with a total value of $122,474.76. Following the acquisition, the insider now owns 13,095,572 shares of the company’s stock, valued at approximately $14,928,952.08. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Thursday, June 27th, Braden Michael Leonard acquired 235,000 shares of Aclaris Therapeutics stock. The shares were purchased at an average cost of $1.15 per share, with a total value of $270,250.00.
• On Monday, June 17th, Braden Michael Leonard purchased 150,000 shares of Aclaris Therapeutics stock. The shares were bought at an average cost of $1.13 per share, for a total transaction of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard purchased 528,621 shares of Aclaris Therapeutics stock. The shares were bought at an average cost of $1.15 per share, for a total transaction of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard bought 1,000,000 shares of Aclaris Therapeutics stock. The shares were acquired at an average cost of $1.08 per share, with a total value of $1,080,000.00.

Aclaris Therapeutics Stock Up 4.5 %

ACRS traded up $0.05 during trading on Monday, hitting $1.15. The company had a trading volume of 1,651,796 shares, compared to its average volume of 1,279,422. The company has a market capitalization of $81.95 million, a PE ratio of -1.06 and a beta of 0.27. Aclaris Therapeutics, Inc. has a one year low of $0.59 and a one year high of $11.12. The firm’s 50-day moving average price is $1.16 and its 200 day moving average price is $1.17.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.04. The business had revenue of $2.40 million for the quarter, compared to analysts’ expectations of $1.99 million. Aclaris Therapeutics had a negative net margin of 248.28% and a negative return on equity of 61.03%. Sell-side analysts forecast that Aclaris Therapeutics, Inc. will post -0.78 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $22.25.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Aclaris Therapeutics by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after buying an additional 207,418 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Aclaris Therapeutics by 5,265.1% during the 1st quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 61,602 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 13,461 shares during the last quarter. Marquette Asset Management LLC acquired a new position in shares of Aclaris Therapeutics during the 1st quarter worth about $104,000. Finally, Deuterium Capital Management LLC acquired a new position in shares of Aclaris Therapeutics during the 1st quarter worth about $99,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.